ADI-270

The CAR T-cell therapy pipeline has experienced significant growth, with over 180 companies actively developing more than 200 innovative cell therapy candidates across various stages of clinical development.

CD40 targeted therapies are under investigation for cancer, autoimmune, and infectious diseases, with the first approval expected by 2027.

Adicet Bio's ADI-001 receives FDA Fast Track designation for refractory systemic lupus erythematosus (SLE) with extrarenal involvement, expediting its development.

Adicet Bio has commenced a Phase 1 clinical trial for ADI-270, an allogeneic gamma delta CAR T-cell therapy, in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC).

Adicet Bio broadens its ADI-001 Phase 1 trial to include six autoimmune indications, with preliminary lupus nephritis data anticipated in the first half of 2025.